Palvella Therapeutics to Host First Quarter 2025 Financial Results and Corporate Update Conference Call on May 15, 2025
Palvella Therapeutics (NASDAQ: PVLA), a clinical-stage biopharmaceutical company specializing in treatments for rare genetic skin diseases, has scheduled its first quarter 2025 financial results and corporate update conference call for May 15, 2025, at 8:30 a.m. ET. The company, which focuses on developing therapies for conditions currently lacking FDA-approved treatments, will provide a webcast with slides accessible through their website's "Events & Presentations" section. Investors can register for dial-in details through a provided link, and a replay will be available approximately 2 hours after the call, remaining archived for 90 days on the company website.
Palvella Therapeutics (NASDAQ: PVLA), una società biofarmaceutica in fase clinica specializzata in trattamenti per malattie genetiche rare della pelle, ha programmato la conferenza telefonica per i risultati finanziari del primo trimestre 2025 e l'aggiornamento aziendale per il 15 maggio 2025 alle 8:30 ET. La società, che si concentra sullo sviluppo di terapie per condizioni attualmente prive di trattamenti approvati dalla FDA, offrirà una webcasting con slide accessibili nella sezione "Eventi e Presentazioni" del loro sito web. Gli investitori possono registrarsi per ricevere i dettagli di accesso tramite un link fornito, e una replica sarà disponibile circa 2 ore dopo la chiamata, rimanendo archiviata per 90 giorni sul sito aziendale.
Palvella Therapeutics (NASDAQ: PVLA), una compañía biofarmacéutica en etapa clínica especializada en tratamientos para enfermedades genéticas raras de la piel, ha programado su llamada de conferencia para los resultados financieros del primer trimestre de 2025 y actualización corporativa para el 15 de mayo de 2025 a las 8:30 a.m. ET. La empresa, que se enfoca en desarrollar terapias para condiciones que actualmente no cuentan con tratamientos aprobados por la FDA, ofrecerá una transmisión web con diapositivas accesibles a través de la sección "Eventos y Presentaciones" en su sitio web. Los inversores pueden registrarse para obtener los detalles de acceso mediante un enlace proporcionado, y una repetición estará disponible aproximadamente 2 horas después de la llamada, permaneciendo archivada por 90 días en el sitio web de la empresa.
Palvella Therapeutics (NASDAQ: PVLA)는 희귀 유전성 피부 질환 치료에 특화된 임상 단계 바이오제약 회사로서, 2025년 1분기 재무 결과 및 기업 업데이트 컨퍼런스 콜을 2025년 5월 15일 오전 8시 30분(동부 표준시)에 예정하고 있습니다. FDA 승인 치료제가 없는 질환에 대한 치료법 개발에 주력하는 이 회사는 웹사이트의 '이벤트 및 프레젠테이션' 섹션을 통해 슬라이드와 함께 웹캐스트를 제공합니다. 투자자들은 제공된 링크를 통해 전화 접속 정보를 등록할 수 있으며, 콜 종료 약 2시간 후 재청취가 가능하며 회사 웹사이트에 90일간 아카이브됩니다.
Palvella Therapeutics (NASDAQ : PVLA), une société biopharmaceutique en phase clinique spécialisée dans les traitements des maladies génétiques rares de la peau, a programmé sa conférence téléphonique sur les résultats financiers du premier trimestre 2025 et la mise à jour de l'entreprise pour le 15 mai 2025 à 8h30 ET. La société, qui se concentre sur le développement de thérapies pour des affections actuellement sans traitements approuvés par la FDA, proposera un webcast avec des diapositives accessibles via la section « Événements & Présentations » de leur site web. Les investisseurs peuvent s'inscrire pour obtenir les détails d'accès via un lien fourni, et un replay sera disponible environ 2 heures après l'appel, restant archivé pendant 90 jours sur le site de l'entreprise.
Palvella Therapeutics (NASDAQ: PVLA), ein biopharmazeutisches Unternehmen in der klinischen Phase, das sich auf Behandlungen seltener genetischer Hauterkrankungen spezialisiert hat, hat seine Telefonkonferenz zu den Finanzergebnissen des ersten Quartals 2025 und einem Unternehmensupdate für den 15. Mai 2025 um 8:30 Uhr ET angesetzt. Das Unternehmen, das Therapien für Erkrankungen entwickelt, für die derzeit keine von der FDA zugelassenen Behandlungen existieren, wird einen Webcast mit Folien anbieten, die über den Bereich "Veranstaltungen & Präsentationen" auf der Website zugänglich sind. Investoren können sich über einen bereitgestellten Link für die Einwahldaten registrieren, und eine Aufzeichnung wird etwa 2 Stunden nach dem Anruf verfügbar sein und 90 Tage lang auf der Unternehmenswebsite archiviert bleiben.
- None.
- None.
WAYNE, Pa., May 08, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: PVLA) Palvella Therapeutics, Inc. (Palvella), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases for which there are no FDA-approved therapies, today announced that it will report its first quarter 2025 financial results on Thursday, May 15, 2025.
Palvella management will host a conference call for investors at 8:30 a.m. ET on Thursday, May 15, 2025, to discuss financial results and provide a corporate update.
To access the live webcast of the call with slides, please click here or visit the "Events & Presentations" section of Palvella’s website. To access the call by phone, please use this registration link, and you will be provided with dial in details. A replay of the webcast will be available approximately 2 hours after the conclusion of the call and archived for 90 days under the "Events & Presentations" section of the Company's website at www.palvellatx.com.
About Palvella Therapeutics
Founded and led by rare disease drug development veterans, Palvella Therapeutics, Inc. (Nasdaq: PVLA) is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases for which there are no FDA-approved therapies. Palvella is developing a broad pipeline of product candidates based on its patented QTORIN™ platform, with an initial focus on serious, rare genetic skin diseases, many of which are lifelong in nature. Palvella’s lead product candidate, QTORIN
QTORIN™ rapamycin is for investigational use only and has not been approved or cleared by the FDA or by any other regulatory agency for any indication.
Contact Information
Investors
Wesley H. Kaupinen
Founder and CEO, Palvella Therapeutics
wes.kaupinen@palvellatx.com
Media
Marcy Nanus
Managing Partner, Trilon Advisors, LLC
mnanus@trilonadvisors.com
FAQ
When will Palvella Therapeutics (PVLA) report Q1 2025 earnings?
How can investors access Palvella Therapeutics' Q1 2025 earnings call?
What is Palvella Therapeutics' (PVLA) main business focus?
How long will the replay of PVLA's Q1 2025 earnings call be available?
